Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials

Fouque-Aubert, Anne; Jette-Paulin, Laetitia; Combescure, Christophe; Basch, A.; Tébib, Jacques; Gossec, Laure

doi:10.1136/ard.2008.098822

Cited by 79 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there are first hints that TNF blockers may be safer in AS compared with RA,31 a decision was made not to create a unique update on the safety of biological agents in AS/spondyloarthritis, but rather to rely on the extensive work done by Furst et al 32 who have undertaken an annual consensus document on this topic from the ‘Targeted therapies’ meeting.…”

Section: Resultsmentioning

confidence: 99%

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

et al. 2011

View full text Add to dashboard Cite

This first update of the ASAS/EULAR recommendations on the management of ankylosing spondylitis (AS) is based on the original paper, a systematic review of existing recommendations and the literature since 2005 and the discussion and agreement among 21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010. Each original bullet point was discussed in detail and reworded if necessary. Decisions on new recommendations were made — if necessary after voting. The strength of the recommendations (SOR) was scored on an 11-point numerical rating scale after the meeting by email. These recommendations apply to patients of all ages that fulfill the modified NY criteria for AS, independent of extra-articular manifestations, and they take into account all drug and non-drug interventions related to AS. Four overarching principles were introduced, implying that one bullet has been moved to this section. There are now 11 bullet points including 2 new ones, one related to extra-articular manifestations and one to changes in the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good.

show abstract

Section: Resultsmentioning

confidence: 99%

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Serious infections may affect any organ system, including the respiratory and the urinary tract, skin and soft tissues, and the musculoskeletal system. The incidence of serious infections is higher in patients with AS under anti-TNF therapy than in those without, although a meta-analysis of 14 randomized controlled trials failed to show a significant difference between those groups [93,94]. Patients who receive TNF blockers should be monitored carefully for signs and symptoms suggestive of infections.…”

Section: Gastrointestinal Toxicitymentioning

confidence: 97%

Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes

Braun¹,

Kiltz²,

Sarholz³

et al. 2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Patient assessment in axial spondyloarthritis (axSpA) is multidimensional, and monitoring of disease activity, function and radiographic progression is complex. There is no simple 'gold standard' for measuring disease activity in all individual patients, as disease activity in axSpA is the sum of many different aspects and a complexity that cannot be represented by a single variable. Limited spinal mobility is a cardinal sign of ankylosing spondylitis and loss of spinal mobility has been reported to be a prognostic factor and most often evaluated with the Bath Ankylosing Spondylitis Functional Index. Imaging of the spine and assessment of safety aspects plays an important role in the monitoring of patients with axSpA. The timeframe for collecting information regarding disease activity, function and radiographic progression are recommended on an individual basis.

show abstract

“…[19,20] Daha az oranda hasta ile yap›lan bir sistematik derleme AS hastalar›nda biyolojik ilaç kullan›m›n›n ciddi infeksiyon geliflimini artt›rmad›¤› yönündedir. [21] Genifl çapl› hastan›n al›nd›¤› retrospektif bir çal›flmada spondilartrit (SpA) grubu hastal›k nedeniyle biyolojik ilaç kullan›m›n›n hastaneye yat›fl gereksinimine neden olacak ciddi infeksiyon geliflimi ile iliflkili olmad›¤›n› rapor etmifltir. [19] TNF-α'n›n granülom oluflumundaki yap› tafllar›ndan biri olmas› nedeniyle bu sitokini engelleyen tedavilerin baflta tüberküloz (Tbc) olmak üzere granülomatöz infeksiyonlara e¤ilim yaratt›¤›n› bildirmifltir.…”

Section: Tart›flmaunclassified

The analysis of ankylosing spondylitis patients receiving biological therapies: data from TURKBIO registry

Güllüoğlu¹

2014

RAED Derg

View full text Add to dashboard Cite

Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials

Cited by 79 publications

References 30 publications

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes

The analysis of ankylosing spondylitis patients receiving biological therapies: data from TURKBIO registry

Contact Info

Product

Resources

About